Bank Of America Corp Precision Biosciences Inc Transaction History

Bank Of America Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.29 - $0.45 $239,267 - $371,276	825,059 Added 2306.31%	860,833 $309,000
Q2 2023 Aug 14, 2023	SELL	$0.52 - $0.91 $1,561 - $2,731	-3,002 Reduced 7.74%	35,774 $18,000
Q1 2023 May 12, 2023	BUY	$0.7 - $1.41 $8,913 - $17,953	12,733 Added 48.89%	38,776 $29,000
Q4 2022 Feb 10, 2023	SELL	$0.97 - $45.0 $1,132 - $52,560	-1,168 Reduced 4.29%	26,043 $30,000
Q3 2022 Nov 14, 2022	SELL	$1.22 - $40.8 $28,277 - $945,662	-23,178 Reduced 46.0%	27,211 $36,000
Q2 2022 Aug 12, 2022	BUY	$1.15 - $3.34 $450 - $1,309	392 Added 0.78%	50,389 $80,000
Q1 2022 May 16, 2022	SELL	$2.96 - $7.76 $457,565 - $1.2 Million	-154,583 Reduced 75.56%	49,997 $155,000
Q4 2021 Feb 08, 2022	BUY	$7.4 - $11.66 $1.11 Million - $1.75 Million	149,937 Added 274.39%	204,580 $1.51 Million
Q3 2021 Nov 15, 2021	BUY	$9.18 - $14.15 $269,772 - $415,826	29,387 Added 116.36%	54,643 $631,000
Q2 2021 Sep 13, 2021	BUY	$8.07 - $12.52 $203,815 - $316,205	25,256 New	25,256 $317,000

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $494M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.